Cargando…
Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most
Miltefosine, the only oral drug approved for the treatment of leishmaniasis—a parasitic disease transmitted by sandflies—is considered as a success story of research and development (R&D) by a public-private partnership (PPP). It epitomises the multiple market failures faced by a neglected disea...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935166/ https://www.ncbi.nlm.nih.gov/pubmed/29736277 http://dx.doi.org/10.1136/bmjgh-2018-000709 |